Trial Profile
A Randomized, Placebo-Controlled, Double-Blind, Dose-Response, Phase 2, -Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2022
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Hot flashes; Vasomotor symptoms
- Focus Therapeutic Use
- Acronyms RDC
- Sponsors Yung Shin Pharmaceutical
- 11 Feb 2022 Status changed from recruiting to completed.
- 14 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.
- 08 Apr 2014 New trial record